克罗恩病和溃疡性结肠炎患者血清中独特的代谢组学和脂质组学特征与健康对照组比较

IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Hauke Christian Tews, Franziska Schmelter, Arne Kandulski, Christa Büchler, Stephan Schmid, Sophie Schlosser, Tanja Elger, Johanna Loibl, Stefanie Sommersberger, Tanja Fererberger, Stefan Gunawan, Claudia Kunst, Karsten Gülow, Dominik Bettenworth, Bandik Föh, Carlos Maaß, Philipp Solbach, Ulrich L Günther, Stefanie Derer, Jens U Marquardt, Christian Sina, Martina Müller
{"title":"克罗恩病和溃疡性结肠炎患者血清中独特的代谢组学和脂质组学特征与健康对照组比较","authors":"Hauke Christian Tews, Franziska Schmelter, Arne Kandulski, Christa Büchler, Stephan Schmid, Sophie Schlosser, Tanja Elger, Johanna Loibl, Stefanie Sommersberger, Tanja Fererberger, Stefan Gunawan, Claudia Kunst, Karsten Gülow, Dominik Bettenworth, Bandik Föh, Carlos Maaß, Philipp Solbach, Ulrich L Günther, Stefanie Derer, Jens U Marquardt, Christian Sina, Martina Müller","doi":"10.1093/ibd/izad298","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Accurate biomarkers for disease activity and progression in patients with inflammatory bowel disease (IBD) are a prerequisite for individual disease characterization and personalized therapy. We show that metabolic profiling of serum from IBD patients is a promising approach to establish biomarkers. The aim of this work was to characterize metabolomic and lipidomic serum profiles of IBD patients in order to identify metabolic fingerprints unique to the disease.</p><p><strong>Methods: </strong>Serum samples were obtained from 55 patients with Crohn's disease (CD), 34 patients with ulcerative colitis (UC), and 40 healthy control (HC) individuals and analyzed using proton nuclear magnetic resonance spectroscopy. Classification of patients and HC individuals was achieved by orthogonal partial least squares discriminant analysis and univariate analysis approaches. Disease activity was assessed using the Gastrointestinal Symptom Rating Scale.</p><p><strong>Results: </strong>Serum metabolome significantly differed between CD patients, UC patients, and HC individuals. The metabolomic differences of UC and CD patients compared with HC individuals were more pronounced than the differences between UC and CD patients. Differences in serum levels of pyruvic acid, histidine, and the branched-chain amino acids leucine and valine were detected. The size of low-density lipoprotein particles shifted from large to small dense particles in patients with CD. Of note, apolipoprotein A1 and A2 serum levels were decreased in CD and UC patients with higher fecal calprotectin levels. The Gastrointestinal Symptom Rating Scale is negatively associated with the concentration of apolipoprotein A2.</p><p><strong>Conclusions: </strong>Metabolomic assessment of serum samples facilitated the differentiation of IBD patients and HC individuals. These differences were constituted by changes in amino acid and lipoprotein levels. Furthermore, disease activity in IBD patients was associated with decreased levels of the atheroprotective apolipoproteins A1 and A2.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2405-2417"},"PeriodicalIF":4.5000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11630276/pdf/","citationCount":"0","resultStr":"{\"title\":\"Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals.\",\"authors\":\"Hauke Christian Tews, Franziska Schmelter, Arne Kandulski, Christa Büchler, Stephan Schmid, Sophie Schlosser, Tanja Elger, Johanna Loibl, Stefanie Sommersberger, Tanja Fererberger, Stefan Gunawan, Claudia Kunst, Karsten Gülow, Dominik Bettenworth, Bandik Föh, Carlos Maaß, Philipp Solbach, Ulrich L Günther, Stefanie Derer, Jens U Marquardt, Christian Sina, Martina Müller\",\"doi\":\"10.1093/ibd/izad298\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Accurate biomarkers for disease activity and progression in patients with inflammatory bowel disease (IBD) are a prerequisite for individual disease characterization and personalized therapy. We show that metabolic profiling of serum from IBD patients is a promising approach to establish biomarkers. The aim of this work was to characterize metabolomic and lipidomic serum profiles of IBD patients in order to identify metabolic fingerprints unique to the disease.</p><p><strong>Methods: </strong>Serum samples were obtained from 55 patients with Crohn's disease (CD), 34 patients with ulcerative colitis (UC), and 40 healthy control (HC) individuals and analyzed using proton nuclear magnetic resonance spectroscopy. Classification of patients and HC individuals was achieved by orthogonal partial least squares discriminant analysis and univariate analysis approaches. Disease activity was assessed using the Gastrointestinal Symptom Rating Scale.</p><p><strong>Results: </strong>Serum metabolome significantly differed between CD patients, UC patients, and HC individuals. The metabolomic differences of UC and CD patients compared with HC individuals were more pronounced than the differences between UC and CD patients. Differences in serum levels of pyruvic acid, histidine, and the branched-chain amino acids leucine and valine were detected. The size of low-density lipoprotein particles shifted from large to small dense particles in patients with CD. Of note, apolipoprotein A1 and A2 serum levels were decreased in CD and UC patients with higher fecal calprotectin levels. The Gastrointestinal Symptom Rating Scale is negatively associated with the concentration of apolipoprotein A2.</p><p><strong>Conclusions: </strong>Metabolomic assessment of serum samples facilitated the differentiation of IBD patients and HC individuals. These differences were constituted by changes in amino acid and lipoprotein levels. Furthermore, disease activity in IBD patients was associated with decreased levels of the atheroprotective apolipoproteins A1 and A2.</p>\",\"PeriodicalId\":13623,\"journal\":{\"name\":\"Inflammatory Bowel Diseases\",\"volume\":\" \",\"pages\":\"2405-2417\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11630276/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammatory Bowel Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ibd/izad298\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammatory Bowel Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ibd/izad298","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:炎症性肠病(IBD)患者疾病活动和进展的准确生物标志物是个体疾病特征描述和个性化治疗的先决条件。我们的研究表明,对 IBD 患者的血清进行代谢分析是建立生物标志物的一种很有前景的方法。这项工作的目的是描述 IBD 患者血清代谢组和脂质组的特征,以确定该疾病特有的代谢指纹:方法:从55名克罗恩病(CD)患者、34名溃疡性结肠炎(UC)患者和40名健康对照组(HC)个体中获取血清样本,并使用质子核磁共振光谱进行分析。通过正交偏最小二乘判别分析和单变量分析方法对患者和健康对照组进行了分类。采用胃肠道症状评分量表评估疾病活动性:结果:CD 患者、UC 患者和 HC 患者的血清代谢组存在明显差异。与 HC 患者相比,UC 和 CD 患者的代谢组差异比 UC 和 CD 患者之间的差异更明显。检测到丙酮酸、组氨酸、支链氨基酸亮氨酸和缬氨酸的血清水平存在差异。在 CD 患者中,低密度脂蛋白颗粒的大小从大颗粒转变为小的致密颗粒。值得注意的是,CD 和 UC 患者的载脂蛋白 A1 和 A2 血清水平降低,粪便钙蛋白水平升高。胃肠道症状评分量表与载脂蛋白A2的浓度呈负相关:血清样本的代谢组学评估有助于区分 IBD 患者和 HC 患者。这些差异由氨基酸和脂蛋白水平的变化构成。此外,IBD患者的疾病活动与保护动脉粥样硬化的脂蛋白A1和A2水平下降有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals.

Background: Accurate biomarkers for disease activity and progression in patients with inflammatory bowel disease (IBD) are a prerequisite for individual disease characterization and personalized therapy. We show that metabolic profiling of serum from IBD patients is a promising approach to establish biomarkers. The aim of this work was to characterize metabolomic and lipidomic serum profiles of IBD patients in order to identify metabolic fingerprints unique to the disease.

Methods: Serum samples were obtained from 55 patients with Crohn's disease (CD), 34 patients with ulcerative colitis (UC), and 40 healthy control (HC) individuals and analyzed using proton nuclear magnetic resonance spectroscopy. Classification of patients and HC individuals was achieved by orthogonal partial least squares discriminant analysis and univariate analysis approaches. Disease activity was assessed using the Gastrointestinal Symptom Rating Scale.

Results: Serum metabolome significantly differed between CD patients, UC patients, and HC individuals. The metabolomic differences of UC and CD patients compared with HC individuals were more pronounced than the differences between UC and CD patients. Differences in serum levels of pyruvic acid, histidine, and the branched-chain amino acids leucine and valine were detected. The size of low-density lipoprotein particles shifted from large to small dense particles in patients with CD. Of note, apolipoprotein A1 and A2 serum levels were decreased in CD and UC patients with higher fecal calprotectin levels. The Gastrointestinal Symptom Rating Scale is negatively associated with the concentration of apolipoprotein A2.

Conclusions: Metabolomic assessment of serum samples facilitated the differentiation of IBD patients and HC individuals. These differences were constituted by changes in amino acid and lipoprotein levels. Furthermore, disease activity in IBD patients was associated with decreased levels of the atheroprotective apolipoproteins A1 and A2.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases 医学-胃肠肝病学
CiteScore
9.70
自引率
6.10%
发文量
462
审稿时长
1 months
期刊介绍: Inflammatory Bowel Diseases® supports the mission of the Crohn''s & Colitis Foundation by bringing the most impactful and cutting edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信